Most complicated deal you've been staffed on

Curious to hear the story and background of the most complicated transaction you have been staffed on. Obviously, don't give any info out that may give away who the parties were.

I wish I had something more exciting to share - my most "exciting" transaction was a multi-part transaction which divested most of the operating entities of the parent company, and the other "part" was a sale of a product line. Needless to say, I wish I had more experience with more complicated transactions such as tax-free spinoffs. Maybe one day..

 

Healthcare deal where company would buy geographic assets from counterparty, counterparty would buy equity in client to fund further research and approval of assets with cash to client based on approval/development milestones and equity based milestones to client based on sales milestones; client wanted counterparty to fund portions of research if trails advanced and counterparty wanted to own more of client if that was the case, so would have option to buy equity at a predetermined price (negotiated premium to stock price). Also contemplated royalty payments to counterparty from client based on sales milestones. Very complicated on a probability weighted NPV value to bridge the gap between parties.

Rationale: counterparty wanted toehold in client, which specialized in non-core assets of counterparty and did not want to take the assets to market. Client wanted to have assets and did not have geographic presence. If deal went well, counterparty had stake that could fend off competition from buying and on a present value made the milestone and royalty payments worthwhile if they did not want to buy them and roll back up with bigger footprint and presence in asset market.

 
George_Banker:
Healthcare deal where company would buy geographic assets from counterparty, counterparty would buy equity in client to fund further research and approval of assets with cash to client based on approval/development milestones and equity based milestones to client based on sales milestones; client wanted counterparty to fund portions of research if trails advanced and counterparty wanted to own more of client if that was the case, so would have option to buy equity at a predetermined price (negotiated premium to stock price). Also contemplated royalty payments to counterparty from client based on sales milestones. Very complicated on a probability weighted NPV value to bridge the gap between parties.

Rationale: counterparty wanted toehold in client, which specialized in non-core assets of counterparty and did not want to take the assets to market. Client wanted to have assets and did not have geographic presence. If deal went well, counterparty had stake that could fend off competition from buying and on a present value made the milestone and royalty payments worthwhile if they did not want to buy them and roll back up with bigger footprint and presence in asset market.

I was thinking of shooting for Investment Banking post MBA, but after reading this post I might need to re evaluate my career goals. I did not understand a word of that post.

 

not sure if this is purposely written to sound more pedantic or complicated than it really is, but this is a very standard licensing agreement, with ownership options, royalties, and clinical trial funding arrangements, dependent on regulatory and commercialization milestones.

Pfizer, Lilly, AZN, JNJ, etc ink these sorts of deals on a quarterly basis. That being said, creating market models across marketed geographies, across patient populations, etc, can be a pain modeling-wise.

 

Deal with 2 industry groups, 2 product groups - first of its kind technology / plant that required multiple tranches of debt and equity raises. At one point pivoted to an infrastructure type model that involved various royalty payments and triggers depending on pricing and volume and split the Company into 2 entities.

Def not as bad as George_Banker's though.

 

Mine wasn't complicated from a structuring standpoint, but our client's primary shareholder (~63%) died 2 days before the final agreement was to be signed. His 5 (yes, fucking 5) kids each got equal share of his ownership, and 2 of the fuckers talked the other 3 into trying to price gouge the counterparty.

Deal fell through. We dropped the relationship. Fun times all around.

 
Best Response

Random biotech company was failing and looking for a way to turn the business around. We lent them debt to finance purchase of bitcoin mining rigs and other bitcoin assets with deal in place to change the name of the Company to include blockchain in the ticker. With plan to refinance debt after name change and issuance of equity.

Original plan was simply to try and keep everyone’s jobs in place by facilitating an eventual equity raise. Plan was hugely successful and stock price sky rocketed 2,000% in 6 weeks. Ownership of company no longer wanted their jobs but tasked us with figuring out best way of liquidating their ownership in company.

They retired and tasked us with negotiating their yacht purchases since our prior Work was incredibly successful.

 

Consectetur accusamus tenetur eos quas non vero. Temporibus nihil quia a dolor debitis. Aut blanditiis est aut omnis aut. Optio incidunt voluptates vel quaerat necessitatibus optio. Eos ipsa et vitae ipsum. Neque non explicabo sit saepe iusto libero.

Ipsam voluptas magni commodi sint et blanditiis pariatur. Quo corporis asperiores aut excepturi maiores aut.

Consequatur laborum et accusamus ipsum et. Autem consectetur eius omnis rerum tempora numquam. Quibusdam placeat error velit rerum at. Repellendus cum labore error et quis.

Qui impedit tenetur voluptatem incidunt fuga autem occaecati. Perspiciatis praesentium at reprehenderit odio et maiores dolore. Quaerat quis vitae et ipsa iste. Magnam iusto qui quos magni molestiae dolores.

Ignore my Title and Industry - I can't seem to change it under 'Edit Profile' lol
 

Reprehenderit quam nam omnis recusandae ea quam. Tenetur vitae est rem optio cum qui nemo voluptatem. Ad est eum quidem et doloremque eum consequatur quo. Sit molestias et dolores et ratione fugiat nisi corporis. Quod et et maxime voluptatem aut provident dolor dolorem. Recusandae sunt minus et corporis ullam earum est.

Ea rerum rerum voluptatem autem. Aut quis error non voluptas dolor distinctio ea.

Career Advancement Opportunities

May 2024 Investment Banking

  • Jefferies & Company 02 99.4%
  • Goldman Sachs 19 98.8%
  • Harris Williams & Co. New 98.3%
  • Lazard Freres 02 97.7%
  • JPMorgan Chase 04 97.1%

Overall Employee Satisfaction

May 2024 Investment Banking

  • Harris Williams & Co. 18 99.4%
  • JPMorgan Chase 10 98.8%
  • Lazard Freres 05 98.3%
  • Morgan Stanley 07 97.7%
  • William Blair 03 97.1%

Professional Growth Opportunities

May 2024 Investment Banking

  • Lazard Freres 01 99.4%
  • Jefferies & Company 02 98.8%
  • Goldman Sachs 17 98.3%
  • Moelis & Company 07 97.7%
  • JPMorgan Chase 05 97.1%

Total Avg Compensation

May 2024 Investment Banking

  • Director/MD (5) $648
  • Vice President (20) $385
  • Associates (88) $260
  • 3rd+ Year Analyst (14) $181
  • Intern/Summer Associate (33) $170
  • 2nd Year Analyst (67) $168
  • 1st Year Analyst (205) $159
  • Intern/Summer Analyst (146) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
BankonBanking's picture
BankonBanking
99.0
3
Betsy Massar's picture
Betsy Massar
99.0
4
Secyh62's picture
Secyh62
99.0
5
GameTheory's picture
GameTheory
98.9
6
kanon's picture
kanon
98.9
7
CompBanker's picture
CompBanker
98.9
8
dosk17's picture
dosk17
98.9
9
bolo up's picture
bolo up
98.8
10
numi's picture
numi
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”